Risk Assessment for Adverse Outcome in Term and Late Preterm Neonates with Bilirubin Values of 20 mg/dL or More

 

 Buy Article Permissions and Reprints

ABSTRACT

The aim of this study is to identify clinical, etiologic, and laboratory factors that potentiate adverse outcome of hyperbilirubinemia among term and late preterm neonates in logistic regression analysis. A retrospective cohort of infants with total serum bilirubin (TSB) ≥ 20 mg/dL from 1995 to 2007 was surveyed. Eighteen infants had adverse outcome. Controls were 270 infants without sequelae. Risks were significantly higher in infants with six etiologies causing hyperbilirubinemia: sepsis (odds ratio [OR] = 161.7, 95% confidence interval [CI] = 11.7 to 2242.8), gastrointestinal obstruction (OR = 39.2, 95% CI = 2.7 to 567.3), Rh incompatibility (OR = 31.0, 95% CI = 5.1 to 188.9), hereditary spherocytosis (OR = 19.6, 95% CI = 1.6 to 235.5), ABO incompatibility (OR = 5.1, 95% CI = 1.3 to 19.7), and glucose-6-phosphate dehydrogenase deficiency (OR = 4.7, 95% CI = 1.3 to 16.7). Infants with acute bilirubin encephalopathy were more likely to have adverse outcome than subjects without acute bilirubin encephalopathy (OR = 281.7, 95% CI = 25.8 to 3076.7). Adverse outcome was more common in infants with a positive direct Coombs test (OR = 4.5, 95% CI = 1.3 to 15.4). Infants with hemoglobin < 10 g/dL tended to have adverse outcome more often than those with hemoglobin ≥ 13 g/dL (OR = 11.8, 95% CI = 3.3 to 42.9). Infants with TSB of 35 mg/dL or more (OR = 472.5, 95% CI = 47.8 to 4668.8) and of 30 to 34.9 mg/dL (OR = 9.5, 95% CI = 1.6 to 57.9) carry greater risks as compared with those with TSB of 20 to 24.9 mg/dL. In conclusion, this study quantitatively verified the potential risks for adverse outcome of neonatal hyperbilirubinemia.

REFERENCES

• 1 Dennery P A, Seidman D S, Stevenson D K. Neonatal hyperbilirubinemia.  N Engl J Med. 2001;  344 581-590
  CrossrefPubMedGoogle Scholar
• 2 Shapiro S M, Bhutani V K, Johnson L. Hyperbilirubinemia and kernicterus.  Clin Perinatol. 2006;  33 387-410
  CrossrefPubMedGoogle Scholar
• 3 Ebbesen F. Recurrence of kernicterus in term and near-term infants in Denmark.  Acta Paediatr. 2000;  89 1213-1217
  CrossrefPubMedGoogle Scholar
• 4 Bhutani V K, Johnson L H, Shapiro S M. Kernicterus in sick and preterm infants (1999–2002): a need for an effective preventive approach.  Semin Perinatol. 2004;  28 319-325
  CrossrefPubMedGoogle Scholar
• 5 Manning D J, Todd P, Maxwell M, Jane Platt M. Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland.  Arch Dis Child Fetal Neonatal Ed. 2007;  92 F342-F346
  CrossrefPubMedGoogle Scholar
• 6 Katar S. Glucose-6-phosphate dehydrogenase deficiency and kernicterus of South-East anatolia.  J Pediatr Hematol Oncol. 2007;  29 284-286
  CrossrefPubMedGoogle Scholar
• 7 Newman T B, Maisels M J. Less aggressive treatment of neonatal jaundice and reports of kernicterus: lessons about practice guidelines.  Pediatrics. 2000;  105 (1 Pt 3) 242-245
  PubMedGoogle Scholar
• 8 Maisels M J, Bhutani V K, Bogen D, Newman T B, Stark A R, Watchko J F. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications.  Pediatrics. 2009;  124 1193-1198
  CrossrefPubMedGoogle Scholar
• 9 Chen W X, Wong V C, Wong K Y. Neurodevelopmental outcome of severe neonatal hemolytic hyperbilirubinemia.  J Child Neurol. 2006;  21 474-479
  PubMedGoogle Scholar
• 10 AlOtaibi S F, Blaser S, MacGregor D L. Neurological complications of kernicterus.  Can J Neurol Sci. 2005;  32 311-315
  PubMedGoogle Scholar
• 11 Yilmaz Y, Karadeniz L, Yildiz F, Degirmenci S Y, Say A. Neurological prognosis in term newborns with neonatal indirect hyperbilirubinemia.  Indian Pediatr. 2001;  38 165-168
  PubMedGoogle Scholar
• 12 Weng Y H, Chou Y H, Lien R I. Hyperbilirubinemia in healthy neonates with glucose-6-phosphate dehydrogenase deficiency.  Early Hum Dev. 2003;  71 129-136
  CrossrefPubMedGoogle Scholar
• 13 American Academy of Pediatrics Subcommittee on Hyperbilirubinemia . Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.  Pediatrics. 2004;  114 297-316
  CrossrefPubMedGoogle Scholar
• 14 Watchko J F. Vigintiphobia revisited.  Pediatrics. 2005;  115 1747-1753
  CrossrefPubMedGoogle Scholar
• 15 Hansen T W. Mechanisms of bilirubin toxicity: clinical implications.  Clin Perinatol. 2002;  29 765-778 viii
  CrossrefPubMedGoogle Scholar
• 16 Johnson L, Bhutani V K, Karp K, Sivieri E M, Shapiro S M. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004).  J Perinatol. 2009;  29 (Suppl 1) S25-S45
  CrossrefPubMedGoogle Scholar
• 17 Weng Y H, Chiu Y W. Comparison of efficacy and safety of exchange transfusion through different catheterizations: femoral vein versus umbilical vein versus umbilical artery/vein.  Pediatr Crit Care Med. 2011;  12 61-64
  CrossrefPubMedGoogle Scholar
• 18 Weng Y H, Chiu Y W. Spectrum and outcome analysis of marked neonatal hyperbilirubinemia with blood group incompatibility.  Chang Gung Med J. 2009;  32 400-408
  PubMedGoogle Scholar
• 19 Berardi A, Lugli L, Ferrari F et al.. Kernicterus associated with hereditary spherocytosis and UGT1A1 promoter polymorphism.  Biol Neonate. 2006;  90 243-246
  CrossrefPubMedGoogle Scholar
• 20 Christensen R D, Henry E. Hereditary spherocytosis in neonates with hyperbilirubinemia.  Pediatrics. 2010;  125 120-125
  CrossrefPubMedGoogle Scholar
• 21 Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus.  Semin Perinatol. 2004;  28 356-364
  CrossrefPubMedGoogle Scholar
• 22 Nair P A, Al Khusaiby S M. Kernicterus and G6PD deficiency—a case series from Oman.  J Trop Pediatr. 2003;  49 74-77
  CrossrefPubMedGoogle Scholar
• 23 Maisels M J, Newman T B. Kernicterus in otherwise healthy, breast-fed term newborns.  Pediatrics. 1995;  96 (4 Pt 1) 730-733
  PubMedGoogle Scholar
• 24 Gourley G R. Breast-feeding, neonatal jaundice and kernicterus.  Semin Neonatol. 2002;  7 135-141
  CrossrefPubMedGoogle Scholar
• 25 Huang M J, Kua K E, Teng H C, Tang K S, Weng H W, Huang C S. Risk factors for severe hyperbilirubinemia in neonates.  Pediatr Res. 2004;  56 682-689
  CrossrefPubMedGoogle Scholar
• 26 Newman T B, Liljestrand P, Escobar G J. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns.  Arch Pediatr Adolesc Med. 2005;  159 113-119
  CrossrefPubMedGoogle Scholar
• 27 Johnson L H, Bhutani V K, Brown A K. System-based approach to management of neonatal jaundice and prevention of kernicterus.  J Pediatr. 2002;  140 396-403
  CrossrefPubMedGoogle Scholar
• 28 Kuzniewicz M, Newman T B. Interaction of hemolysis and hyperbilirubinemia on neurodevelopmental outcomes in the collaborative perinatal project.  Pediatrics. 2009;  123 1045-1050
  CrossrefPubMedGoogle Scholar

Yi-Hao WengM.D. 

Division of Neonatology, Department of Pediatrics, Chang Gung Memorial Hospital

199 Dunhua North Road, Taipei 105, Taiwan, ROC

Email: yihaoweng@adm.cgmh.org.tw